login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
DYNE THERAPEUTICS INC (DYN) Stock News
USA
- NASDAQ:DYN -
US26818M1080
-
Common Stock
12.58
USD
-0.59 (-4.48%)
Last: 9/25/2025, 8:00:02 PM
12.2356
USD
-0.34 (-2.74%)
After Hours:
9/25/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
DYN Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics to Present at Upcoming Investor Conferences
a month ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics to Present at Upcoming Investor Conferences
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
2 months ago - By: The Motley Fool
Dyne Reports Wider Loss in Fiscal Q2
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Dyne Therapeutics, Inc. - DYN
2 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
2 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
2 months ago - By: Benzinga
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss
2 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
2 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
3 months ago - By: Yahoo Finance
- Mentions:
RY
RY.CA
GM
HTGC
RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
3 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
3 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
3 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
3 months ago - By: Benzinga
- Mentions:
AVAV
PODD
PRGS
TSLA
...
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
3 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
3 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock
3 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
3 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
3 months ago - By: Dyne Therapeutics, Inc.
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
3 months ago - By: Dyne Therapeutics, Inc.
- Mentions:
HTGC
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
Please enable JavaScript to continue using this application.